- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Data Protection
- Design
- Digital Marketing Rights
- DRM
- Electronics
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Germany’s Boehringer Repudiated Patent on HIV Drug- Nevirapine
The Indian Patent Office has repudiated Germany’s Boehringer Ingelheim patent on its key HIV drug- Nevirapine, Patent Application Number: 4724/DELNP/2009 entitled “Extended-release formulation of Nevirapine”, for a version sold as Viramune XR (extended-release), once again forestalling attempts by Big Pharma for “exclusivity” extension on their patented drugs to reportedly block entry of reasonably priced generics. … Continue reading Germany’s Boehringer Repudiated Patent on HIV Drug- Nevirapine
Read more »Indian Patent office rejects Patent claim over Abraxane
In a major setback, the Indian Patent Office denied a patent to an anti-cancer drug Abraxane manufactured by US-Based Abraxis BioSciences. Here we will discuss the decision given by IPO at the backdrop of the arguments advanced by the respective parties. Background In a brief, Patent application no. 2899/DELNP/2005 filed by Abraxis Biosciences was earlier … Continue reading Indian Patent office rejects Patent claim over Abraxane
Read more »Why Protecting Patents in India is Giving Hard Time to Drug Patent Holders
May 22, 2014 - 10:34 am
Categories:
India
IP Litigation
News & Updates
Patent Litigation
Patents
Pharma/Biotech Patent Litigations
0 Comments
Introduction A lot has been discussed on the Novartis ruling indicating much higher standards of patentability under Indian law under section 3d. The ruling decided that any new form of known compound (in medicine) would be patentable only if there is enhanced ‘therapeutic efficacy’ over the known compound. Post Novartis ruling, a couple of patent … Continue reading Why Protecting Patents in India is Giving Hard Time to Drug Patent Holders
Read more »Sofosbuvir: The Next Pre-Grant Opposition Target by I-MAK
After anti-influenza drug Tamiflu (Oseltamivir Phosphate) and antiretroviral drug Viread, Gilead Sciences is again back in news, this time with its hepatitis C (HCV) drug Sofosbuvir. Like Tamiflu and Viread’s pre-grant opposition, Sofosbuvir patent application is also facing pre-grant opposition. Non-profit group I-MAK (Initiative for medicines access and knowledge) has filed a pre-grant opposition against … Continue reading Sofosbuvir: The Next Pre-Grant Opposition Target by I-MAK
Read more »GSK’s patent on lapatinib ditosylate revoked by IPAB
August 8, 2013 - 9:36 am
Categories:
IP Practice in India
Pharma/Biotech Patent Litigations
0 Comments
GSK’s granted patent IN221171 (‘171) on lapatinib ditosylate (marketed as Tykerb), a tyrosine kinase inhibitor for treating breast cancer, was revoked by IPAB by its order of 27th July 2013. A revocation application was filed by Fresenius Kabi Oncology Limited. The patent is revoked on the ground of non-compliance with S.3d alone on basis of … Continue reading GSK’s patent on lapatinib ditosylate revoked by IPAB
Read more »The Glivec saga in India is finally over
As it has been widely covered by media in and outside India, it is no new news to the pharmaceutical and patent fraternity that Novartis has lost about the 7-year long legal battle to secure patent protection for its invention on the beta crystalline form of imatinib mesylate in India. A 112 page long Supreme … Continue reading The Glivec saga in India is finally over
Read more »Roche’s Struggle Over its Patents in India – Two suits, Two oppositions
The struggle between innovator pharmaceutical companies (mostly in the Western world) and developing world Generic companies have been lately played out in India and especially for the last 2-3 years in the form of litigations and oppositions. Here I would be discussing the specific case of Roche (a Swiss Pharma Company) showcasing its journey of … Continue reading Roche’s Struggle Over its Patents in India – Two suits, Two oppositions
Read more »